Calyxo key facts
as of Oct 2026- Developer of minimally invasive medical devices designed to improve kidney stone treatment outcomes.
- Calyxo is valued at approximately $684.6M as of Oct 2026, set at its later-stage round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $166.0M across 4 recorded rounds; the latest was Early Stage VC ($40.1M) in Apr 2026.
- Notable investors include Ally Bridge Group, Avidity Partners, CRG, Janus Henderson Investors, Questa Capital — 7 tracked in total.
- Calyxo has filed 4 Form Ds with the SEC since 2022, most recently Apr 2026 ($40.1M sold to 12 investors).
- Status: Privately Held (backing).
Valued at $684.6M at its later-stage round, Apr 2026. Nothing has traded since.
- ·Watch Calyxo: the Monday email on marks, rounds and moves
Calyxo funding rounds
4 roundsCalyxo valuation
Calyxo was valued at $685 million at its later-stage round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Calyxo raised?
Calyxo has raised $166 million across 4 recorded rounds since 2022. The largest was a $50 million later-stage round in Oct 2023; the most recent was a $40.1 million early-stage round in Apr 2026.
Calyxo has filed 4 Form Ds with the SEC since 2022, most recently in Apr 2026 ($40.1 million sold to 12 investors).
Calyxo investors
7 investors are on record for Calyxo, including Ally Bridge Group, Avidity Partners, CRG and Janus Henderson Investors. The early-stage round in Apr 2026 drew 12 investors.
About Calyxo
Developer of minimally invasive medical devices designed to improve kidney stone treatment outcomes. The company offers a ureteroscopy-based system with integrated laser lithotripsy for stone fragmentation, continuous irrigation for visualization and procedural control, dynamic aspiration for active removal of stone fragments and debris, and stone collection capabilities to ensure complete extraction, enabling urologists and healthcare providers to achieve stone clearance rates, reduce residual fragments, and improve overall patient outcomes in kidney stone treatment.
- Sector
- Healthcare
- HQ
- Pleasanton, CA, United States
- Founded
- 2016
- Employees
- 321
- Website
- calyxoinc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.